期刊文献+

非小细胞肺癌分子靶向治疗的最新研究进展 被引量:10

在线阅读 下载PDF
导出
摘要 随着肿瘤生物学、基因组学和分子生物学的发展,靶向治疗的研究和临床应用已成为当前肺癌领域的热点。本文对国内外有关非小细胞肺癌分子靶向治疗的靶点和主要药物进行了综述。首先概括了表皮生长因子受体抑制剂,其次总结了肿瘤血管生成抑制剂,包括抗血管内皮生长因子单克隆抗体、血管内皮抑素和金属蛋白酶抑制剂的研究,最后对新的靶点EML4-ALK抑制剂的研发进行了跟踪。未来肺癌靶向治疗药物的开发和临床应用会达到更加成熟的阶段。
出处 《天津药学》 2015年第1期44-46,共3页 Tianjin Pharmacy
  • 相关文献

参考文献27

  • 1Jemal A, Bray F,Center M M,et ul. Global cancer statistics [ J ]. CA - Cancer J Clin, 2011,61 ( 2 ) :69 - 90.
  • 2Sreenath V, Sharma S V, Daphne W, et al. Epidermal growth factor re- ceptor mutations in lung cancer [ J ] Nat Rev Cancer, 2007,7 (3) : 169 - 181.
  • 3Bimhaum A, Ready New. Gefitinib therapy for non - small cell lung cancer [ J]. Curt Treat Options Onco1,2005,6( 1 ) :75 - 81.
  • 4Mok T S. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarci- noma [J]. N Engl J Med,2009,361 (10) :947 -957.
  • 5Zhou C, Wu Y L, Chen G, et al. Erlotinib versus ehemotherapy as first - line treatment for patients with advanced EGFR mutation - positive non - small - cell lung cancer ( OPTIMAL, CTONG - 0802 ) : a multi - centre,open - label, randomised, phase 3 study [ J ]. Lancet Oncol, 2011,12:735 - 742.
  • 6曾越灿,蔡炜嵩,吴荣,迟峰,邢锐,肖玉平,辛彦,王乃乾.厄洛替尼治疗终末期非小细胞肺癌的疗效观察[J].疑难病杂志,2014,13(3):278-280. 被引量:11
  • 7Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemo- therapy as first - line treatment for European patients with advanced EG- FR nmtation - positive non - snmll - cell lung cancer (EURTAC) : a muhicentre,open - label, randomised phase3 trial [ J ]. Lancet Oncol, 2012,13:239 - 246.
  • 8Q zhou, J shcn, J shentu, et al. A phase I/II a study of icotinib hydrochloride,a novel oral EGFR - TK1, to evaluate its safety, toler- ance, and preliminary efficacy in advanced NSCLC patients in china [ J ]. J Clin Onco1,2010,28,15s ( sl ) :7574.
  • 9Sun Y, Shi Y, Zhang L, et al. A randomized, double - blind phase 11I study of icotinib versus gefitinib in patients with advanced non - small cell lung cancer (NSCLC) previously treated with chemotherapy (ICO- GEN ) [ J ]. J Clin Onco1,2011,29 (sl) : a7522.
  • 10鲍明亮,毕清,田青,赵明利,任宏轩.埃克替尼二、三线治疗48例晚期非小细胞肺癌[J].中国肿瘤,2014,23(3):249-252. 被引量:5

二级参考文献62

  • 1潘振奎,张力,张星,王欣,李宁,徐菲,常建华,管忠震.中国非小细胞肺癌患者表皮生长因子受体突变的研究[J].癌症,2005,24(8):919-923. 被引量:44
  • 2王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:627
  • 3董强刚,黄进肃,黄建,卢丽琴,杨立民.肺癌靶向治疗研究进展与我国肺癌的EGFR基因突变概况[J].肿瘤,2005,25(6):625-628. 被引量:35
  • 4何秋山,易铁男,张凌云,孙志华.国产吉西他滨联合卡铂治疗晚期非小细胞肺癌的临床观察[J].中国肺癌杂志,2006,9(1):82-83. 被引量:7
  • 5Finerty M J, Bingham J P, Hartley J A, et al. Azino- mycin bisepoxides containing rigid aromatic linkers: Synthesis, cytotoxicity and DNA interstrand cross-link- ing activity [ J ]. Tetrahedron Letters, 2009,50 ( 26 ) : 3648 - 3650.
  • 6Mahindroo N, Punchihewa C, Fujii N. Hedgehog-gli signaling pathway inhibitors as anticancer agents [ J ]. Journal of Medicinal Chemestry,2009,52 ( 13 ) : 3829 - 3845.
  • 7Suzuki N, Suzuki T, Ota Y, et al. Design,synthesis, and biological activity of boronlc acid-based histone deacetylase inhibitors [ J ]. Journal of Medicinal Cheme- stry ,2009 ,52 (9) : 2909 - 2922.
  • 8Castellano S, Milite C, Ragno R, et al. Design, syn- thesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 ( AMI-1 ) [ J ]. Journal of Medicinal Chemestry, 2010,5 ( 3 ) : 398 - 414.
  • 9Yu M, Lizarzaburu M, Beckmann H, et al. Identifica- tion of piperaziae-hlsamide GHSR axttagonists for the treatment of obesity [ J ]. Bioorganic & Medicinal Chemistry Letters ,2010,20(5 ) : 1758 - 1762.
  • 10Descoteaux C, Leblanc V, Brasseur K, et al. Synthe- sis of D- and L-tyrosine-chlorambucil analogs active a- gainst breast cancer cell lines [ J ]. Bioorganic & Me- dicinal Chemistry Letters ,2010,20 (24) :7388 - 7392.

共引文献40

同被引文献114

引证文献10

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部